Shanghai Pharma Stock Continues Fall Despite Denial Of Securities Investigation
This article was originally published in PharmAsia News
Executive Summary
Refuting an investigation and M&A malfeasance hasn't prevented shares from tumbling for Shanghai Pharma, which has Pfizer Inc. as a cornerstone investor.